AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families

NEXT STORY
FDA approves Novartis Piqray® – the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
PREV STORY
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & Med Tech Summit

author_avatar
NASDAQ Market News

Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020

author_avatar
NASDAQ Market News

MDxHealth (R): MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis

author_avatar
NASDAQ Market News